Description Patients who fulfill eligibility criteria will be entered into the trial to receive Palbociclib
After the screening procedures confirm participation in the research study:
Palbociclib- Fixed Dose, daily for 21 days per cycle.
The participant will be requested to maintain a medication diary of each dose of medication. The medication diary will be returned to clinic staff at the end of each cycle.